EyePoint Pharmaceuticals, Inc. (EYPT) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 696K | 620K | 966K | 5.33M | 24.45M | 11.59M | 10.52M | 9.48M | 11.68M | 14.03M | 15.2M | 9.11M |
| Revenue Growth % | -97.15% | -94.65% | -90.82% | -43.73% | 109.29% | -17.39% | -30.77% | 4.09% | 52.08% | 33.18% | 51.84% | -21.27% |
| Cost of Goods Sold | 528K | 375K | 721K | 165K | 805K | 816K | 736K | 1.4M | 759K | 998K | 1.2M | 1.79M |
| COGS % of Revenue | 75.86% | 60.48% | 74.64% | 3.09% | 3.29% | 7.04% | 6.99% | 14.78% | 6.5% | 7.11% | 7.91% | 19.68% |
| Gross Profit | 168K | 245K | 245K | 5.17M | 23.65M | 10.77M | 9.79M | 8.08M | 10.93M | 13.03M | 14M | 7.31M |
| Gross Margin % | 24.14% | 39.52% | 25.36% | 96.91% | 96.71% | 92.96% | 93.01% | 85.22% | 93.5% | 92.89% | 92.09% | 80.32% |
| Gross Profit Growth % | -99.29% | -97.73% | -97.5% | -36.01% | 116.46% | -17.33% | -30.09% | 10.43% | 55.12% | 82.93% | 62.66% | -25.61% |
| Operating Expenses | 87.39M | 70.59M | 62.27M | 67.39M | 72.48M | 56.01M | 42.54M | 42.62M | 44.25M | 29.38M | 28.4M | 30.07M |
| OpEx % of Revenue | 12556.61% | 11385.48% | 6446.17% | 1263.74% | 296.43% | 483.35% | 404.18% | 449.74% | 378.69% | 209.47% | 186.8% | 330.3% |
| Selling, General & Admin | 15.25M | 11.38M | 14.52M | 11.9M | 13.91M | 12.64M | 12.99M | 12.8M | 14.11M | 11.43M | 11.04M | 14.34M |
| SG&A % of Revenue | 2190.52% | 1834.84% | 1502.69% | 223.08% | 56.89% | 109.07% | 123.47% | 135.06% | 120.74% | 81.5% | 72.59% | 157.54% |
| Research & Development | 72.15M | 59.21M | 47.75M | 55.5M | 58.57M | 43.37M | 29.54M | 29.82M | 30.14M | 17.95M | 17.36M | 15.73M |
| R&D % of Revenue | 10366.09% | 9550.65% | 4943.48% | 1040.65% | 239.54% | 374.28% | 280.71% | 314.68% | 257.95% | 127.97% | 114.22% | 172.76% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -87.23M | -70.34M | -62.02M | -62.23M | -48.84M | -45.24M | -32.75M | -34.55M | -33.32M | -16.35M | -14.4M | -22.76M |
| Operating Margin % | -12532.47% | -11345.97% | -6420.81% | -1166.83% | -199.72% | -390.4% | -311.17% | -364.52% | -285.18% | -116.58% | -94.71% | -249.98% |
| Operating Income Growth % | -78.61% | -55.5% | -89.4% | -80.13% | -46.57% | -176.62% | -127.45% | -51.78% | -54.59% | 62.61% | 21.74% | -18.45% |
| EBITDA | -87.23M | -70.34M | -61.45M | -61.69M | -48.34M | -44.77M | -32.34M | -34.18M | -33.02M | -16.24M | -14.28M | -22.63M |
| EBITDA Margin % | -12532.47% | -11345.97% | -6361.18% | -1156.74% | -197.69% | -386.37% | -307.3% | -360.7% | -282.59% | -115.78% | -93.95% | -248.53% |
| EBITDA Growth % | -80.44% | -57.12% | -90.01% | -80.46% | -46.41% | -175.66% | -126.42% | -51.06% | -53.94% | 62.58% | 19.25% | -22.24% |
| D&A (Non-Cash Add-back) | 0 | 0 | 576K | 538K | 497K | 467K | 408K | 362K | 303K | 112K | 115K | 132K |
| EBIT | -87.23M | -70.34M | -59.73M | -62.23M | -48.84M | -41.3M | -29.36M | -30.83M | -29.28M | -14.02M | -12.61M | -22.48M |
| Net Interest Income | 2.34M | 2.92M | 2.29M | 2.89M | 3.64M | 3.93M | 3.39M | 3.72M | 4.04M | 2.34M | 1.79M | 1.19M |
| Interest Income | 2.34M | 2.92M | 2.29M | 2.89M | 3.64M | 3.94M | 3.39M | 3.72M | 4.04M | 2.34M | 1.79M | 1.62M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 14K | 0 | 0 | 0 | 0 | 0 | 435K |
| Other Income/Expense | 2.34M | 2.92M | 2.29M | 2.89M | 3.64M | 3.93M | 3.39M | 3.72M | 4.04M | 2.34M | 1.79M | -159K |
| Pretax Income | -84.88M | -67.42M | -59.73M | -59.33M | -45.2M | -41.31M | -29.36M | -30.83M | -29.28M | -14.02M | -12.61M | -22.92M |
| Pretax Margin % | -12195.69% | -10874.68% | -6183.44% | -1112.56% | -184.82% | -356.48% | -278.99% | -325.27% | -250.63% | -99.91% | -82.96% | -251.73% |
| Income Tax | 50K | -186K | 0 | 93K | 0 | 90K | 0 | 0 | 0 | 83K | 0 | 0 |
| Effective Tax Rate % | -0.06% | 0.28% | 0% | -0.16% | 0% | -0.22% | 0% | 0% | 0% | -0.59% | 0% | 0% |
| Net Income | -84.83M | -67.61M | -59.73M | -59.43M | -45.2M | -41.4M | -29.36M | -30.83M | -29.28M | -14.1M | -12.61M | -22.92M |
| Net Margin % | -12188.51% | -10904.68% | -6183.44% | -1114.31% | -184.82% | -357.26% | -278.99% | -325.27% | -250.63% | -100.51% | -82.96% | -251.73% |
| Net Income Growth % | -87.7% | -63.31% | -103.44% | -92.78% | -54.33% | -193.63% | -132.8% | -34.49% | -38.37% | 67.55% | 31.53% | -18.11% |
| Net Income (Continuing) | -84.93M | -67.24M | -59.73M | -59.43M | -45.2M | -41.4M | -29.36M | -30.83M | -29.28M | -14.1M | -12.61M | -22.92M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.99 | -0.81 | -0.85 | -0.85 | -0.65 | -0.64 | -0.54 | -0.58 | -0.55 | -0.33 | -0.33 | -0.61 |
| EPS Growth % | -52.31% | -26.56% | -57.41% | -46.55% | -18.18% | -93.94% | -63.64% | 4.92% | 5.17% | 80.81% | 32.65% | -17.31% |
| EPS (Basic) | -0.99 | -0.81 | -0.85 | -0.85 | -0.65 | -0.64 | -0.54 | -0.58 | -0.55 | -0.33 | -0.33 | -0.61 |
| Diluted Shares Outstanding | 86M | 83.03M | 70.17M | 69.93M | 69.77M | 64.56M | 54.45M | 53.21M | 52.91M | 42.17M | 38.34M | 37.58M |
| Basic Shares Outstanding | 86M | 83.03M | 70.17M | 69.93M | 69.77M | 64.56M | 54.45M | 53.21M | 52.91M | 42.17M | 38.34M | 37.58M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |